Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
about
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapyStructured treatment interruptions (STI) in chronic unsuppressed HIV infection in adultsStructured treatment interruptions (STI) in chronic suppressed HIV infection in adultsModelling the impact of antiretroviral use in resource-poor settingsEscape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness lossOptimal timing and duration of induction therapy for HIV-1 infectionOnly slight impact of predicted replicative capacity for therapy response predictionTransmitted minority drug-resistant HIV variants: a new epidemic?Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacityFirst line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyResidual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolutionEstimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in GermanyHIV drug resistance mutations in proviral DNA from a community treatment programEstimating HIV-1 fitness characteristics from cross-sectional genotype dataHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactMutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAARTA fossil record of zidovudine resistance in transmitted isolates of HIV-1A consensus surface activation marker signature is partially dependent on human immunodeficiency virus type 1 Nef expression within productively infected macrophagesThe latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance.Adaptation of HIV-1 depends on the host-cell environment.Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsReappearance of an 11-year-old sequence in an HIV-1 infected patient during treatment interruption.Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells.Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kineticsUltrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.Genotypic testing for human immunodeficiency virus type 1 drug resistance.HIV preferentially infects HIV-specific CD4+ T cells.The use of pooled viral load testing to identify antiretroviral treatment failureMinority variants of drug-resistant HIV.Optimal antiviral switching to minimize resistance risk in HIV therapy.Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.
P2860
Q24243499-93C1C185-13D2-4E05-A8FC-57B5309C7B3AQ24245541-040F73F6-5A2C-40C0-9EFB-0CDFFAE2729DQ24245709-2C8F3388-D48B-4BF7-94A8-39DBAEA8484BQ25255753-8B378D49-787A-44E8-BBA0-50D012A1E9AFQ28469223-9CDC33CB-F288-498F-A6AB-1EBB9E5B1B8EQ28469250-07918C62-62AA-475A-BBD5-E1E28A2E2B9CQ28472749-0C13A946-7335-41C6-AABD-00F0C644EEC6Q28473302-EF75BE29-DAB0-4E0A-B370-587CA2C1EDE9Q28477017-82244A63-7EF4-46DD-9ED5-677E688924A8Q28538326-4654B66F-BEF7-4177-B968-5D63C8D5A2F8Q28539563-2F06C107-A96B-4CA9-89B3-9778EBACFEF6Q28542508-D7075798-8C11-49AF-A975-E236B4B5B67AQ28543156-16E88245-D3FF-4F59-BA2B-858A757A59ECQ28544753-53805B8D-51D3-4C23-963A-E37205279371Q28552455-CAABD6B2-ACAA-4146-A3AE-2348472C12CBQ28552784-27B1ECD1-46E4-4CE2-A07F-F8D798DBAE18Q28775685-50442094-F0A1-42DE-80A7-0D3CD5B90F30Q30009511-02BC61E3-6C1C-4FB8-8D48-11430C204EE9Q33212237-3704D84D-4B12-41C2-99C3-7EEE29B42A70Q33277177-848F94BE-69F2-40A5-80E7-E600902E820CQ33299456-F9540B03-AEA1-442F-AF5A-F976C8BBCDFCQ33302143-6D21D9B1-AF7D-49C6-986A-19EB162106E1Q33574798-46FDCE64-DB6C-4203-98C9-4E937004396FQ33592278-D33BDFA7-5065-49F5-A10A-E2D2D7779605Q33592427-5F149549-1A7D-4F09-A77E-A693D17B3FA9Q33644248-09B08F90-8077-4077-BF79-4FF7D5862054Q33721788-34FE793C-0779-446E-8167-9026940D0B56Q33724247-490949B7-9EA5-47A5-A208-3CBFBE0647A6Q33760825-0675BD28-4E78-4ED9-9778-17FAE9036035Q33780566-699E36CA-15C9-4D81-A77B-E6E03217B202Q33798207-001698C1-C4FE-4516-8CC1-CB688BDA9528Q33827841-363E7765-B857-491B-A652-CCC6EEC3228AQ33843040-7AE57699-ECF1-4DB7-A566-9D20D616938EQ33906239-B79F40B3-4EF8-42DA-964D-F23FB006175CQ33958893-EB1D0DA0-4F1B-4FE4-96E1-9AA09BD9B773Q34043003-06BE34A8-762C-4386-9B34-FC2A14A79F4DQ34047780-815309DA-821C-4C63-9D36-5ADAE6A6F900Q34071754-4005CBE1-08BB-4F99-BAD3-51BEA83C1B81Q34087809-3151BEFA-6CFD-4B54-8227-702D705F71AAQ34328792-95A176A7-0DE9-43D4-B1D1-7460E61BFC86
P2860
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Virologic and immunologic cons ...... ients with detectable viremia.
@en
Virologic and immunologic cons ...... ients with detectable viremia.
@nl
type
label
Virologic and immunologic cons ...... ients with detectable viremia.
@en
Virologic and immunologic cons ...... ients with detectable viremia.
@nl
prefLabel
Virologic and immunologic cons ...... ients with detectable viremia.
@en
Virologic and immunologic cons ...... ients with detectable viremia.
@nl
P2093
P1476
Virologic and immunologic cons ...... tients with detectable viremia
@en
P2093
Barbour JD
Hellerstein MK
Hellmann NS
Petropoulos CJ
P304
P356
10.1056/NEJM200102153440702
P407
P577
2001-02-01T00:00:00Z